NCT01265615 - Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients | Biotech Hunter

Enrollment

109

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

April 30, 2010

Study Completion Date

September 30, 2010

Conditions

Cardiorenal SyndromeChronic Allograft Nephropathy

Interventions

DRUG

Paricalcitol

paricalcitol group (6-8 μg daily per os - orally - without special diet)

DRUG

Calcitriol

calcitriol group (2-4 μg daily orally under with dietary restrictions of vitamin D)

DRUG

Cholecalciferol

cholecalciferol group (intake of cholecalciferol with recommended daily allowance equals 1200-2400 IU per day)

DIETARY_SUPPLEMENT

Supplemental

intake of cholecalciferol in food and multivitamins, less than 400-900 IU per day

Trial Locations (2)

Ural Institute of Cardiology, Yekaterinburg

De Haar Research Foundation, Rotterdam